New Sedative Fails to Beat Propofol on Day-One Recovery After Knee Surgery

For millions of people each year, arthroscopic knee surgery is a routine affair: a camera, a shaver, a small repair of the meniscus, and home the same day. Yet the anesthetic that keeps patients still and unaware during those forty-five minutes has long been a matter of quiet debate among anesthesiologists. Propofol, the milky-white drug made famous by its use in celebrity sedation, has dominated total intravenous anesthesia for decades. Now a newer agent, remimazolam, has been challenging that dominance with promises of gentler blood pressure control and smoother wake-ups. A randomized controlled trial published in PLOS One by Eunah Cho, Ha Yan Kim, Yangjin Kim, and Seokyung Shin set out to answer a deceptively simple question: does the choice between these two sedatives actually change how patients feel on the day after surgery?

The researchers focused on a metric that has become the gold standard in modern perioperative medicine: quality of recovery, measured with the validated QoR-40 questionnaire. Unlike traditional outcome measures that track only complications or vital signs, the QoR-40 asks patients directly about five dimensions of their experience — emotional state, physical comfort, psychological support, physical independence, and pain. Scores range from 40 to 200, with higher numbers reflecting better recovery. In minor orthopedic surgery, where most patients expect to walk out of the hospital within hours, this patient-reported measure is arguably the outcome that matters most. A drug that leaves patients feeling foggy, nauseated, or emotionally flat on the first postoperative day undermines the entire premise of ambulatory surgery, no matter how elegant its pharmacology looks on a monitor.

The trial enrolled eighty adults scheduled for elective arthroscopic meniscectomy and randomly assigned them to receive either propofol-based or remimazolam-based total intravenous anesthesia. Both techniques maintained anesthesia entirely through intravenous agents, avoiding inhaled gases, and both were paired with standardized analgesia protocols. Seventy-one patients ultimately completed the QoR-40 questionnaire and entered the final analysis, split into thirty-six in the propofol group and thirty-five in the remimazolam group. The primary endpoint was the global QoR-40 score on postoperative day one, a time point chosen because it captures the window when most ambulatory surgical patients are already back home, judging whether the operation was worth the trouble.

The headline result was, in statistical terms, a null finding. Global QoR-40 scores on the first day after surgery did not differ significantly between the two anesthetic regimens. Patients who received propofol scored 166.1 plus or minus 16.8, while those who received remimazolam scored 170.6 plus or minus 13.6 — a mean difference of 4.5 points, with a 95 percent confidence interval spanning from minus 11.8 to 2.7 and a P value of 0.218. In plain language, the overall quality of recovery one day out was statistically indistinguishable between the two drugs. For clinicians who have been weighing a switch to the newer, considerably more expensive agent, this finding suggests that the patient-centered payoff, at least in this surgical context, may not justify the change on its own.

But the trial’s secondary and exploratory analyses tell a more textured story, one that anesthesiologists will read closely. In an exploratory analysis of the questionnaire’s subdomains, the emotional-state scores were significantly higher in the remimazolam group, at 39.2 plus or minus 2.5 compared with 37.0 plus or minus 4.3 in the propofol group — a mean difference of 2.2 points with a confidence interval of minus 3.9 to minus 0.6 and a P value of 0.009. Patients who received remimazolam reported feeling emotionally better on the day after surgery. Whether this reflects less residual sedative hangover, a gentler pharmacological off-ramp, or simply chance in a modest sample is a question the authors themselves flag as requiring confirmation, since the finding emerged from an exploratory rather than a pre-specified primary analysis. Still, mood disturbances after anesthesia are a real and underappreciated problem, and any signal pointing toward improved emotional recovery deserves attention.

The intraoperative data reveal why remimazolam has generated such enthusiasm in the first place. Hypotension severe enough to require ephedrine, a vasopressor used to rescue falling blood pressure, occurred in 44.4 percent of the propofol group but only 17.1 percent of the remimazolam group, a difference that reached statistical significance with a P value of 0.013. This hemodynamic stability is not a trivial nicety. Blood pressure dips under general anesthesia reduce perfusion to vital organs, and in vulnerable patients — the elderly, those with cardiac disease — repeated hypotensive episodes have been linked in larger studies to postoperative organ injury and even mortality. Remimazolam, a benzodiazepine derivative metabolized rapidly by carboxylesterases into inactive metabolites, offers a pharmacological profile that buffers against the vasodilation and myocardial depression characteristic of propofol. The trial’s hemodynamic results align neatly with that mechanistic expectation.

The trade-off, however, appeared in the recovery room. Patients in the remimazolam group took longer to become fully alert, with a median time of 37 minutes compared with 18 minutes in the propofol group, a difference so pronounced that the P value fell below 0.001. Their stay in the post-anesthesia care unit was also longer, with a median of 38 minutes versus 30 minutes, significant at P equals 0.008. This is the pharmacological irony at the heart of the study: remimazolam was designed to be ultra-short-acting, theoretically allowing faster wake-ups than propofol, whose context-sensitive half-time depends on redistribution and slower hepatic metabolism. Yet in this trial, the benzodiazepine left patients drowsier for longer in the immediate aftermath. One plausible explanation lies in dosing strategy and the reversal agent flumazenil, which was not routinely deployed; another is that benzodiazepine sedation, even when chemically brief, produces a subjective heaviness that outlasts the drug’s plasma presence. Whatever the mechanism, the finding complicates the marketing narrative of remimazolam as a faster-on, faster-off anesthetic.

What does this mean for the average patient facing a knee scope? The reassuring message is that both anesthetics delivered comparable overall recovery by the next day, with no dramatic divergence in pain, nausea, or global well-being. The choice between them is unlikely to transform the experience of a healthy adult undergoing minor orthopedic surgery. The more nuanced message is that the drugs differ in character rather than in overall quality: propofol gets patients alert faster but stresses their circulation more, while remimazolam protects blood pressure but lingers in consciousness a little longer and may leave patients in a slightly brighter mood the following morning. Anesthesiologists tailoring care to individual patients — say, a patient with hypertension or cardiac risk who would benefit from hemodynamic stability, versus a patient eager to drive home as early as possible — now have trial evidence to inform that conversation.

The study also illustrates a broader shift in how anesthesia research is conducted and judged. For decades, the field measured success in terms of intraoperative variables: heart rate, blood pressure, bispectral index values, emergence times. The QoR-40 and its successor instruments have pushed investigators to ask whether all those monitor-friendly optimizations actually translate into patients feeling better. By anchoring its primary outcome on patient-reported recovery, this trial embodies that philosophy — and its null result is itself informative, demonstrating that a hemodynamically superior anesthetic does not automatically produce a superior patient experience. The gap between physiological elegance and subjective well-being remains one of the most interesting frontiers in perioperative science.

Limitations temper the conclusions, as they do in any trial of this size. With seventy-one analyzed patients, the study was powered to detect a meaningful difference in global QoR-40 scores but not to resolve smaller effects in secondary endpoints, and the emotional-state finding will need replication in larger, more diverse cohorts before it can guide practice. The restriction to elective arthroscopic meniscectomy in adults also leaves open whether the same balance of benefits and costs would hold in major surgery, in older populations, or in procedures with different pain profiles. Still, the trial delivers a clear and clinically useful verdict: in the contest between remimazolam and propofol for day surgery, neither drug claims the crown of better overall recovery, and the decision may come down to which trade-off — circulatory stability or speed of alertness — matters more for the individual in the operating chair.

Subject of Research: Comparison of postoperative quality of recovery between remimazolam-based and propofol-based total intravenous anesthesia in arthroscopic meniscectomy

Article Title: Quality of recovery after arthroscopic meniscectomy with remimazolam or propofol anesthesia: A randomized controlled trial

Article References: Cho, E., Kim, H. Y., Kim, Y., & Shin, S. (2026). Quality of recovery after arthroscopic meniscectomy with remimazolam or propofol anesthesia: A randomized controlled trial. PLOS One, 21(10), e0360759. https://doi.org/10.1371/journal.pone.0360759

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360759

Keywords: remimazolam, propofol, total intravenous anesthesia, quality of recovery, QoR-40, arthroscopic meniscectomy, randomized controlled trial, hypotension, postoperative recovery, anesthesiology, ambulatory surgery, patient-reported outcomes